A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
Resource Type
Article
Authors
Gonzalez, Maria ; Van Akkooi, Alexander Christopher Jonathan ; Spillane, Andrew John ; Ch'ng, Sydney ; Shannon, Kerwin Frank ; Stretch, Jonathan ; Rtshiladze, Michael Alexander ; Pennington, Thomas ; Saw, Robyn P.M. ; Menzies, Alexander M. ; Rawson, Robert V ; Martin, Linda ; Guitera, Pascale ; Gregorio, Mary Jane ; London, Kevin ; Kapoor, Rony ; Hsiao, Edward ; Lo, Serigne N. ; Scolyer, Richard A. ; Long, Georgina V.
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9610-TPS9610, 1p
Subject
Language
ISSN
0732183X